From the Journals

Women with lung cancer live longer than men


 

FROM THE JOURNAL OF THORACIC ONCOLOGY

Screening guidelines

Commenting on the findings in an accompanying editorial, Claudia Poleri, MD, Hospital María Ferrer, Buenos Aires, says that this Australian study provides “valuable information.”

“The risk of dying from lung cancer was significantly higher for men than for women,” she writes. “Differences in treatment-related factors explained 50% of the sex survival differential, followed by lifestyle and tumor-related factors (28% and 26%, respectively).

“Nevertheless, these differences alone do not explain the higher survival in women,” she comments.

“Does it matter to analyze the differences by sex in lung cancer?” Dr. Poleri asks in the editorial, and then answers herself: “It matters.”

“It is necessary to implement screening programs and build artificial intelligence diagnostic algorithms considering the role of sex and gender equity to ensure that innovative technologies do not induce disparities in clinical care,” she writes.

“It is crucial to conduct education and health public programs that consider these differences, optimizing the use of available resources, [and] it is essential to improve the accuracy of research design and clinical trials,” she adds.

Dr. Yu and Dr. Poleri declared no relevant financial interests.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Stage I NSCLC: No real-world survival benefit with tegafur-uracil chemotherapy
MDedge Hematology and Oncology
Unresectable stage III NSCLC: Platinum-doublet chemotherapy beneficial as second-line therapy
MDedge Hematology and Oncology
Advanced nonsquamous NSCLC: First-line ICI-chemo tops bevacizumab-chemo in OS
MDedge Hematology and Oncology
Advanced NSCLC: Adding antiangiogenic drug to second-line therapy boosts survival outcomes
MDedge Hematology and Oncology
High D-dimer levels tied to mortality and VTE risks in patients with lung cancer
MDedge Hematology and Oncology
EU approves new blood and lung cancer drugs
MDedge Hematology and Oncology
Fifth COVID shot recommended for patients with cancer
MDedge Hematology and Oncology
Clinical Edge Journal Scan Commentary: Recent Lung Cancer Trial Results, May 2022
MDedge Hematology and Oncology
Clinical chest images power up survival prediction in lung cancer
MDedge Hematology and Oncology
Dodging potholes from cancer care to hospice transitions
MDedge Hematology and Oncology